Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion BioSpaceThe new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) BioSpace The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen positions MariTide as potential ‘best monthly’ obesity drugNext: Pfizer, Arvinas join SERD club with Veppanu approval Related Stories Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026
